Table 1.
Baseline Characteristics by Treatment Group and Diagnosis
| Characteristic | Mean (SD)a
|
|||
|---|---|---|---|---|
| GHRH Group
|
Placebo Group (n = 16)
|
|||
| Normal Cognitive Function | MCI | Normal Cognitive Function | MCI | |
| Participants, No. (No. female) | 6 (3) | 8 (2) | 7 (3) | 9 (4) |
| Age, y | 66.8 (9.0) | 69.4 (8.3) | 64.4 (8.7) | 70.1 (7.2) |
| Educational level, y | 17.5 (2.6) | 17.8 (2.4) | 16.7 (2.5) | 16.8 (2.0) |
| MMSE | 29.3 (1.0) | 29.4 (1.4) | 29.4 (0.5) | 28.8 (1.5) |
| Story recall scoreb | 60.3 (14.3) | 40.1 (16.4) | 60.0 (11.6) | 44.7 (12.8) |
| BMI | 25.7 (3.2) | 28.1 (3.9) | 25.3 (5.0) | 27.4 (3.4) |
| IGF-1, ng/mL | 158 (92) | 231 (78) | 206 (66) | 161 (46) |
| Insulin, μIU/mL | 4.2 (0.8) | 8.0 (5.6) | 5.5 (3.7) | 6.4 (3.8) |
| Glucose, mg/dL | 97 (7.2) | 104 (11.0) | 93 (6.5) | 97 (12.1) |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); GHRH, growth hormone–releasing hormone; glucose, fasting plasma glucose concentration; IGF-1, fasting serum concentration of insulinlike growth factor 1; insulin, fasting plasma insulin concentration; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination score (maximum score, 30).
SI conversion factors: To convert IGF-1 to nanomoles per liter, multiply by 0.131; insulin to picomoles per liter, by 6.945; and glucose to millimoles per liter, by 0.0555.
a
Data represent mean (SD) values unless otherwise noted.
b
Significant baseline difference by diagnosis (P <.05).